Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.74 |
| ▸ | RECQL | P46063 | 1/20 | 0.70 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.62 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.59 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.53 |
| ▸ | MAPT | P10636 | 3/20 | 0.53 |
| ▸ | MEN1 | O00255 | 2/20 | 0.53 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.53 |
| ▸ | HTT | P42858 | 1/20 | 0.49 |
| ▸ | ATM | Q13315 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24507059 | 0.94 | GAA (0.71) | GAARECQLALDH1A1TDP1CYP1A2 | |
| SCHEMBL22326350 | 0.91 | GAA (0.88) | GAARECQLALDH1A1TDP1CYP1A2 | |
| SCHEMBL3431305 | 0.91 | RECQL (0.69) | GAARECQLALDH1A1TDP1CYP1A2 | |
| SCHEMBL4853171 | 0.88 | GAA (0.65) | GAARECQLALDH1A1TDP1CYP1A2 | |
| SCHEMBL2472798 | 0.88 | ALDH1A1 (0.70) | GAARECQLALDH1A1TDP1CYP1A2 | |
| SCHEMBL28432135 | 0.88 | GAA (0.65) | GAARECQLALDH1A1TDP1CYP1A2 | |
| SCHEMBL17770699 | 0.88 | GAA (0.65) | GAARECQLALDH1A1TDP1CYP1A2 | |
| SCHEMBL14560518 | 0.88 | TDP1 (0.76) | GAARECQLALDH1A1TDP1CYP1A2 | |
| SCHEMBL2538210 | 0.88 | GAA (0.65) | GAARECQLALDH1A1TDP1CYP1A2 | |
| SCHEMBL12513630 | 0.87 | GAA (0.62) | GAARECQLALDH1A1TDP1CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2398822-B1 | MODIFICATION OF FACTOR VIII | NOVO NORDISK AS (DK) | 2013-01-02 | — | — | EP | disclosed |
| EP-2398822-B1 | MODIFICATION OF FACTOR VIII | NOVO NORDISK AS (DK) | 2013-01-02 | — | — | EP | disclosed |
| US-20110306551-A1 | Modification of Factor VIII | NOVO NORDISK A/S (DK) | 2011-12-15 | — | — | US | disclosed |
| US-20110306551-A1 | Modification of Factor VIII | NOVO NORDISK A/S (DK) | 2011-12-15 | — | — | US | disclosed |
| US-20110306551-A1 | Modification of Factor VIII | NOVO NORDISK A/S (DK) | 2011-12-15 | — | — | US | disclosed |
| WO-2010102886-A1 | MODIFICATION OF FACTOR VIII | NOVO NORDISK A/S (DK) | 2010-09-16 | — | — | WO | disclosed |
| EP-1393053-A1 | ION SENSITIVE ELECTRODES BASED ON OXA-AZAMACROCYCLES AS IONOPHORE FOR THE DETERMINATION OF NITRATE, SALICYLATE, OR PERIODATE ANIONS | The Robert Gordon University (GB) | 2004-03-03 | — | — | EP | disclosed |
| WO-2002099409-A1 | ION SENSITIVE ELECTRODES BASED ON OXA-AZAMACROCYCLES AS IONOPHORE FOR THE DETERMINATION OF NITRATE, SALICYLATE OR PERIODATE ANIONS | THE ROBERT GORDON UNIVERSITY (GB) | 2002-12-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110306551-A1 | Modification of Factor VIII | F8, F9, F13B | GAA 1830/4885RECQL 2594/4885ALDH1A1 3132/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.